C. Yoshida

发表

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.

J. Melo, S. Basu, K. Igarashi, 2007, Blood.

Association of non‐alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia

T. Iijima, Y. Hasegawa, H. Kojima, 2004, European journal of haematology.

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

T. Nakao, J. Sakamoto, J. Nishida, 2018, International Journal of Clinical Oncology.

Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.

J. Sakamoto, T. Kumagai, K. Ohashi, 2014, Journal of clinical and experimental hematopathology : JCEH.

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

T. Miyamoto, M. Kizaki, A. Mori, 2022, International Journal of Hematology.

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

T. Miyamoto, C. Dinardo, N. Komatsu, 2021, Japanese journal of clinical oncology.

Cytotoxic T-Cell Lymphoma Arising in Behçet Disease

Y. Hasegawa, H. Kojima, T. Nagasawa, 2003, International journal of hematology.

Rapidly Progressive Lennert's Lymphoma Terminating in Fulminant Hepatic Failure

H. Kojima, T. Nagasawa, N. Mori, 2003, Leukemia & lymphoma.

Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial

H. Kojima, T. Kumagai, K. Ohashi, 2019, Acta Haematologica.

Efficacy and safety of bortezomib-containing induction chemotherapy for autologous stem cell transplantation-eligible Japanese multiple myeloma patients — A phase 2 multicenter trial —

H. Kojima, T. Kumagai, K. Ohashi, 2015 .

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.

J. Sakamoto, H. Ureshino, S. Kimura, 2021, The Lancet. Haematology.

Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy

J. Sakamoto, M. Shiseki, S. Morita, 2017, International Journal of Clinical Oncology.

Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

J. Sakamoto, S. Morita, T. Kumagai, 2016, Oncology reports.

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.

J. Sakamoto, S. Morita, T. Kumagai, 2018, Leukemia research.

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

J. Sakamoto, S. Morita, T. Kumagai, 2015, American journal of hematology.

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

J. Sakamoto, S. Morita, T. Kumagai, 2017, Cancer science.

Treatment of PNH hemolytic crisis with heparin or low-molecular weight heparin by its dual (anticomplement and anti-coagulant) activity

Y. Hasegawa, T. Nagasawa, C. Yoshida, 2003 .

A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits

T. Naoe, N. Uike, I. Matsumura, 2015, International Journal of Hematology.

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

J. Sakamoto, S. Morita, T. Kumagai, 2015, American journal of hematology.

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy

T. Miyamoto, A. Wei, J. Kuroda, 2021, Japanese journal of clinical oncology.

Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

J. Sakamoto, T. Kumagai, K. Ohashi, 2020, International Journal of Hematology.

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

K. Mitani, N. Takahashi, T. Kondo, 2014, Biomarker Research.

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

Y. Hasegawa, H. Kojima, K. Suzukawa, 2011, International journal of hematology.

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

J. Sakamoto, T. Kumagai, K. Ohashi, 2013, International Journal of Hematology.

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

J. Sakamoto, S. Morita, T. Kumagai, 2020, Cancer science.

Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever

S. Yamasaki, Hideyuki Yamamoto, Shiro Tanaka, 2020, Mycoses.

Impact of the Clinical Trials Act on Noncommercial Clinical Research in Japan: An Interrupted Time-series Analysis

Y. Imanaka, C. Yoshida, T. Komeno, 2021, medRxiv.

Diffuse Large B-Cell Lymphoma Carrying both

H. Ohtani, C. Yoshida, T. Komeno, 2011 .

Diffuse large B-cell lymphoma carrying both t(3 ; 7)(q27 ; p12) and t(8 ; 14)(q24 ; q32).

H. Ohtani, C. Yoshida, T. Komeno, 2011, Internal medicine.

Association of pyoderma gangrenosum and sterile osteomyelitis in a patient having myelodysplastic syndrome with der(1;7)(q10;q10)

F. Otsuka, Y. Hasegawa, H. Kojima, 2004, European journal of haematology.

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study

K. Fushimi, Y. Imanaka, S. Morita, 2019, International Journal of Clinical Oncology.

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

Yohei Owada, Toshiki Terao, Yoshiaki Abe, 2022, Nature Cell Biology.

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

T. Oda, Yohei Owada, Toshiki Terao, 2022, Nature cell biology.

Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

J. Melo, C. Yoshida, 2004, International journal of hematology.

T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p.

Y. Hasegawa, H. Kojima, T. Nagasawa, 2004, Cancer genetics and cytogenetics.

Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5

J. Melo, K. Igarashi, M. Makri, 2013, Leukemia.

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

J. Sakamoto, Toshikazu Yamaguchi, M. Shiseki, 2012, International Journal of Clinical Oncology.

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

T. Naoe, I. Matsumura, Y. Kanakura, 2016, SpringerPlus.

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

J. Sakamoto, S. Morita, T. Kumagai, 2016 .

A patient with acquired pure red cell aplasia showing a positive antiglobulin test and the presence of inhibitor against erythroid precursors.

Y. Hasegawa, H. Kojima, T. Nagasawa, 2002, Internal medicine.

HIV-associated peripheral T-cell lymphoma with a cytotoxic phenotype.

H. Ohtani, C. Yoshida, T. Komeno, 2014, Internal medicine.

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma

H. Kojima, H. Mukai, C. Yoshida, 2015, Acta Haematologica.

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.

T. Miyamoto, K. Ishizawa, S. Takada, 2023, Japanese journal of clinical oncology.

K. Mitani, N. Takahashi, T. Kondo, 2014, Biomarker Research.

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

S. Kimura, H. Kojima, T. Kumagai, 2023, International Journal of Hematology.

Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma. -a Phase 2 Multicenter Trial-

H. Kojima, T. Kumagai, K. Ohashi, 2018, Blood.

Relevance of the Daily Dose of Imatinib Mesylate (IM) Rather Than Its Trough Plasma Concentration for Achieving Deep Molecular Response in Patients with Chronic Myeloid Leukemia.

Y. Hasegawa, H. Kojima, K. Suzukawa, 2009 .

Primary Intramuscular Classic Hodgkin Lymphoma: A Rare Case Report

Y. Miura, H. Ohtani, Y. Inadome, 2021, Internal medicine.